|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC149 |
Gene summary for CCDC149 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC149 | Gene ID | 91050 |
| Gene name | coiled-coil domain containing 149 | |
| Gene Alias | CCDC149 | |
| Cytomap | 4p15.2 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q6ZUS6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91050 | CCDC149 | male-WTA | Human | Thyroid | PTC | 5.16e-03 | 3.56e-02 | 0.1037 |
| 91050 | CCDC149 | PTC01 | Human | Thyroid | PTC | 4.43e-02 | 3.80e-02 | 0.1899 |
| 91050 | CCDC149 | PTC05 | Human | Thyroid | PTC | 1.32e-03 | 2.03e-01 | 0.2065 |
| 91050 | CCDC149 | PTC07 | Human | Thyroid | PTC | 5.87e-04 | 1.07e-01 | 0.2044 |
| 91050 | CCDC149 | ATC12 | Human | Thyroid | ATC | 2.41e-03 | 5.51e-02 | 0.34 |
| 91050 | CCDC149 | ATC13 | Human | Thyroid | ATC | 2.19e-47 | 7.73e-01 | 0.34 |
| 91050 | CCDC149 | ATC2 | Human | Thyroid | ATC | 2.35e-02 | 3.12e-01 | 0.34 |
| 91050 | CCDC149 | ATC4 | Human | Thyroid | ATC | 1.81e-02 | 9.05e-02 | 0.34 |
| 91050 | CCDC149 | ATC5 | Human | Thyroid | ATC | 2.99e-47 | 8.20e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC149 | insertion | Nonsense_Mutation | novel | c.267_268insCTGGCAAGGAGTTGGAAATGAATC | p.Ala89_Asn90insLeuAlaArgSerTrpLysTerIle | p.A89_N90insLARSWK*I | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
| CCDC149 | SNV | Missense_Mutation | rs199742117 | c.751C>T | p.Arg251Trp | p.R251W | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| CCDC149 | SNV | Missense_Mutation | novel | c.305N>C | p.Asn102Thr | p.N102T | protein_coding | tolerated(0.06) | benign(0.073) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CCDC149 | SNV | Missense_Mutation | c.953G>T | p.Arg318Met | p.R318M | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CCDC149 | insertion | Frame_Shift_Ins | novel | c.1002_1003insA | p.Leu335IlefsTer39 | p.L335Ifs*39 | protein_coding | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |||
| CCDC149 | SNV | Missense_Mutation | rs371760511 | c.893N>A | p.Ser298Tyr | p.S298Y | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC149 | SNV | Missense_Mutation | c.212N>G | p.Tyr71Cys | p.Y71C | protein_coding | deleterious(0) | possibly_damaging(0.905) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CCDC149 | SNV | Missense_Mutation | novel | c.458N>C | p.Leu153Ser | p.L153S | protein_coding | deleterious(0) | benign(0.17) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| CCDC149 | SNV | Missense_Mutation | novel | c.416N>T | p.Ala139Val | p.A139V | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
| CCDC149 | SNV | Missense_Mutation | c.440N>T | p.Ala147Val | p.A147V | protein_coding | deleterious(0.01) | probably_damaging(0.941) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |